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The outgrowth of new from preexisting lym-
phatic vessels (lymphangiogenesis) has recently 
gained  wide  attention  for  its  involvement  in   
tumor metastasis and induction of alloimmunity 
after transplantation (Stacker et al., 2002; Chen 
et al., 2004; Cursiefen et al., 2004a; Kerjaschki, 
2006; Kerjaschki et al., 2006). Lymphangiogene-
sis is mainly induced by ligation of vascular en-
dothelial growth factor (VEGF)-C and  VEGF-D 
to their high-affinity receptor  VEGFR3 on lym-
phatic vascular endothelium (Carmeliet and Jain, 
2000; Stacker et al., 2002). Additionally, fibro-
blast  growth  factor  (FGF)  and VEGF-A  have 
been  reported  to  support  lymphangiogenesis 
(Kubo et al., 2002; Nagy et al., 2002; Cursiefen 
et  al.,  2004b;  Bock  et  al.,  2007).  Exogenous 
pharmacological inhibitors of lymphangiogene-
sis include corticosteroids (Boneham and Collin, 
1995), VEGF-A–specific cytokine traps (VEGF 
TrapR1R2;  Cursiefen  et  al.,  2004a),  inhibitory 
peptides against integrin 5/v, and blocking an-
tibodies against  VEGF receptor 3 (Cursiefen et al., 
2005; Dietrich et al., 2007; Bock et al., 2008) or 
VEGF-A (Bock et al., 2007). Although several 
lymphangiogenic  growth  factors  and  their   
exogenous inhibitors are already characterized, 
only one endogenous inhibitor of lymphatic 
outgrowth has been identified thus far (soluble 
VEGFR2; Albuquerque et al., 2009).
The avascular nature of the cornea is attrib-
uted to the presence of several antihemangio-
genic factors, such as thrombospondin-1 (TSP-1) 
and TSP-2, angiostatin, endostatin, pigment   
epithelium–derived  factor,  and  IL-1  receptor 
antagonist (Chang et al., 2001), which are be-
lieved to maintain the hemangiogenic privilege 
in this tissue. Besides these factors, receptor de-
coy mechanisms such as ectopically expressed 
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Lymphangiogenesis plays an important role in tumor metastasis and transplant outcome. Here, 
we show that thrombospondin-1 (TSP-1), a multifunctional extracellular matrix protein and 
naturally occurring inhibitor of angiogenesis inhibits lymphangiogenesis in mice. Compared with 
wild-type mice, 6-mo-old TSP-1–deficient mice develop increased spontaneous corneal lymph-
angiogenesis. Similarly, in a model of inflammation-induced corneal neovascularization, 
young TSP-1–deficient mice develop exacerbated lymphangiogenesis, which can be reversed by 
topical application of recombinant human TSP-1. Such increased corneal lymphangiogenesis is 
also detected in mice lacking CD36, a receptor for TSP-1. In these mice, repopulation of corneal 
macrophages with predominantly WT mice via bone marrow reconstitution ameliorates their 
prolymphangiogenic phenotype. In vitro, exposure of WT macrophages to TSP-1 suppresses 
expression of lymphangiogenic factors vascular endothelial growth factor (VEGF)-C and  
VEGF-D, but not of a primarily hemangiogenic factor VEGF-A. Inhibition of VEGF-C is not 
detected in the absence or blockade of CD36. These findings suggest that TSP-1, by ligating 
CD36 on monocytic cells, acts as an endogenous inhibitor of lymphangiogenesis.
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Isolated outgrowth of LYVE-1+++/CD31+ lymphatic vessels 
was detectable beyond the limbal vascular arcade into the 
normally avascular and alymphatic central cornea in 6-mo-old 
TSP-1/ mice (Fig. 1, A–D). Occasionally, these lymphatic 
VEGFR3 and soluble VEGFR1 (Ambati et al., 2006; Cursiefen 
et al., 2006) also help to maintain the avascular status of the 
cornea. Similarly, it is quite possible that the alymphatic   
nature of the cornea is also maintained by multiple endog-
enously expressed factors with antilymphangiogenic proper-
ties besides soluble VEGFR2 (Albuquerque et al., 2009). 
Knowledge about endogenous inhibitors of lymphangiogen-
esis not only facilitates a better understanding of the regula-
tion of lymphangiogenesis in vivo but also explains the 
alymphatic nature of certain tissues, such as cartilage and cor-
nea. Considering the potential therapeutic benefit (e.g., in 
tumor metastasis and transplantation immunology) of such 
inhibitors, we were interested in identifying additional en-
dogenous antilymphangiogenic factors.
Many exogenous antihemangiogenic factors have been 
recently demonstrated to exhibit antilymphangiogenic prop-
erties (Bock et al., 2007). Thrombospondin-1 and -2 consti-
tute an antiangiogenic subfamily (Armstrong and Bornstein, 
2003; Lawler, 2000, 2002) of matricellular glycoproteins 
known as thrombospondins. Both isoforms are constitutively 
expressed in the mouse cornea (Armstrong and Bornstein, 
2003; Cursiefen et al., 2004c; Sekiyama et al., 2006). TSP-1, 
which binds and activates latent TGF-, inhibits hemangio-
genesis through both direct effect on endothelial cell migra-
tion and survival (e.g., by inducing vascular endothelial cell 
apoptosis through binding to CD36; Jiménez et al., 2000), as 
well as through indirect effects on growth factor mobilization 
(e.g., by binding heparin sulfate proteoglycans [Lawler, 2000, 
2002]). In addition it was shown that TSP-1 inhibits corneal 
hemangiogenesis in vivo (Simantov et al., 2001; Cursiefen   
et al., 2004c). Here, we evaluated the potential antilymphan-
giogenic role of TSP-1 using the mouse model of concurrent 
induction of hemangiogenesis and lymphangiogenesis into 
the normally avascular cornea (Cursiefen et al., 2004b).   
We provide evidence that TSP-1 indeed inhibits lymphangio-
genesis and effectively regulates the expression of the main 
lymphangiogenic  growth  factor VEGF-C  in  inflammatory 
macrophages. The  antilymphangiogenic  effect  of TSP-1 
under inflammatory conditions seems to be mediated indi-
rectly via down-regulation of lymphangiogenic growth factor 
VEGF-C expression in bone marrow–derived macrophages 
through CD36 ligation. This opens new treatment avenues 
for the modulation of inflammatory pathological lymphangio-
genesis in the context of tumor growth and transplantation.
RESULTS
Increased lymphangiogenesis is detectable in TSP-1/ mice
To analyze a potential antilymphangiogenic effect of TSP-1, we 
first evaluated corneal lymphangiogenesis in TSP-1/ mice. 
Corneas of TSP-1/ and WT C57BL/6 control mice were   
examined biomicroscopically and immunohistochemically   
for the lymphatic vessel marker LYVE-1 and pan-endothelial 
cell marker CD31. Although the corneas did not display any 
biomicroscopic evidence of blood vessel growth into the 
cornea, mild (clinically invisible) spontaneous growth of 
lymphatic vessels was detectable by specific immunostaining.   
Figure 1.  TSP-1/ mice display mild isolated lymphangiogenesis.  
(A–D) Immunofluorescence analysis of LYVE-1+++/CD31+ lymphatic vessels  
(L, arrows) emanating from the limbal arcade (Li) toward the center of the 
cornea in 6-mo-old TSP-1/ (A-C) or WT (control, D) mice. Blood vessels  
(B, arrowheads) in the limbal arcade stain intensely with anti-CD31, but not 
with anti–LYVE-1. (E) Electron micrograph of the corneal stromal lymphatic 
vessel in TSP-1/ mice showing erythrocyte-free lumen (Lu). Arrowheads 
denote the thin endothelial lining with absent basement membrane and ab-
sent pericyte coverage. Inset shows higher magnification view. (F and G) WT 
control and TSP-1/ complete corneal flat-mounts stained with LYVE-1  
(Li, limbus, arrowhead; L, lymphatic vessel, arrow). Note isolated lymphatic 
vessel traversing the whole cornea in G (L, arrow). (H) Morphometric compari-
son demonstrates a significantly increased spontaneous corneal lymphangio-
genesis in TSP-1/ mice compared with WT controls (*, P < 0.05; n = 10; all 
mice aged 6 mo). (I) Morphometric quantification of lymphatic vessels in the 
ear skin from young (p10) or adult (p30) WT and TSP-1/ mice (*, P < 0.05;  
n = 5 per group, compared with WT controls). Error bars indicate SD. JEM VOL. 208, May 9, 2011 
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antilymphangiogenic effect of TSP-1 occurs via interfering 
with VEGF-C–mediated mechanism, we compared transcrip-
tion levels of VEGF-C mRNA in corneas derived from WT 
and age-matched TSP-1/ mice (pooled from n = 5–8) of 
different ages (8 wk and 6 mo). As depicted in Fig. 3 A, the 
corneas of younger TSP-1/ mice did not express signifi-
cantly increased mRNA levels for VEGF-C compared with 
WT controls. However, at 6 mo of age VEGF-C expression   
in TSP-1/ corneas increased to more than eightfold com-
pared with age-matched WT controls (Fig. 3 B). These results 
are consistent with the absence of spontaneous corneal lym-
phangiogenesis in young TSP-1/ mice and increase de-
tected in older mice.
Under inflammatory conditions, macrophages are known to 
be the primary source of the lymphangiogenic factor VEGF-C 
(Schoppmann et al., 2002; Cursiefen et al., 2004b; Kerjaschki, 
2005; Maruyama et al., 2005, 2007). Moreover, the corneal 
stroma is endowed with significant numbers of resident   
macrophages (Brissette-Storkus et al., 2002). Therefore we ex-
amined by flow cytometry numbers of CD11b+ macrophages 
in corneas harvested from 6-mo-old WT and TSP-1/ mice. 
The increased numbers of CD11b+ macrophages detectable 
in TSP-1/ corneas (Fig. 3 C) coincided with the increased 
expression of corneal  VEGF-C at this age compared with WT 
controls (Fig. 3 B). These data suggest that the absence of 
TSP-1 results in increased expression of the lymphangiogenic 
vessels were found extending from the limbus through the 
corneal apex to the other side (Fig. 1 G). These LYVE-1+++/
CD31+ lymphatic vessels were not accompanied by CD31+++/
LYVE-1 blood vessels (Fig. 1 C). Transmission electron   
microscopy of the central cornea confirmed the immunohisto-
chemical findings by demonstrating lymph vessels with typical 
ultrastructural features (Fig. 1 E; Cursiefen et al., 2002). Mor-
phometric  comparison  of  the  area  covered  by  LYVE-1+++/
CD31+ lymphatic vessels in TSP-1/ and age-matched WT 
control corneas (Fig. 1 H) revealed that the area covered by 
lymphatic vessels was significantly larger in the TSP-1/ 
corneas as compared with that in WT control mice (P < 0.001; 
n = 10).
To determine whether the antilymphangiogenic effect of 
TSP-1 is detectable in tissues other than cornea, we evaluated 
the lymphatic vessels in typically highly lymphvascularized 
tissue, such as skin. Comparing the ear skins of TSP-1/ and 
age-matched WT mice, we noted a significant increase of lym-
phatic vessel density in adult (p30) and young (p10) TSP-1/ 
mice (P < 0.05; Fig. 1 I), suggesting that TSP-1 has anti-
lymphangiogenic effects in different tissues.
Because spontaneous corneal lymphangiogenesis was de-
tectable only in older (6-mo-old) TSP / mice, we next ex-
amined if corneas in younger animals exposed to inflammatory 
stimuli respond with increased lymphangiogenesis. We used 
the mouse model of suture-induced, inflammation-associated 
corneal neovascularization (Cursiefen et al., 2004a,b). 1 wk 
after intrastromal placement of three 11–0 nylon sutures in 
TSP-1/ and WT mice, corneas were excised and the lymph-
vascularized  area  was  measured  using  morphometry. As 
seen in Fig. 2 C, a significant increase in lymphangiogenesis 
was detected in TSP-1/ mice compared with WT controls 
(P < 0.05; n = 10). In addition, we analyzed the effect of ex-
ogenous recombinant TSP-1 on lymphangiogenesis in vivo. 
WT mice received a subconjunctival injection of recombi-
nant TSP-1 (50 ng/50 µl) before suture placement, followed 
by a topical treatment with TSP-1 eye drops for 7 d and two 
more subconjunctival injections on day 3 and 5. 1 wk after 
intrastromal suture placement, corneas were excised and the 
hemvascularized and lymphvascularized area measured us-
ing morphometry. As shown in Fig. 2 D, lymphangiogenesis 
was significantly inhibited (58.3 ± 12.8%; P < 0.05). In ad-
dition, blood vessel outgrowth was impaired significantly 
(81.4 ± 5.7%; P < 0.05; unpublished data) as expected. These 
findings confirm an inhibitory effect of TSP-1 in inflammation-
associated lymphangiogenesis.
Expression of lymphangiogenic factor VEGF-C is increased 
in TSP-1/ corneas
Lymphangiogenic effects of VEGF-C have been reported 
previously (Enholm et al., 2001; Kubo et al., 2002; Stacker   
et al., 2002). Binding of this growth factor to its receptor 
(VEGFR3) expressed on lymphatic endothelium is known to 
induce lymphangiogenesis. It is therefore conceivable that   
interference with this receptor ligand interaction may result 
in inhibition of lymphangiogenesis. To test whether the   
Figure 2.  TSP-1 regulates the lymphangiogenic response in a 
mouse model of inflammation-associated corneal neovasculariza-
tion. Representative segments of corneal flat mounts from WT and  
TSP-1/ mice stained with CD31 are shown in green (blood vessels) and 
LYVE-1 is shown in red (lymphatic vessels; A; Li, Limbal vascular arcade: 
bottom, center of the cornea: top; B; L, lymph vessels). (C) Morphometric 
quantification of lymphvascularized area in WT and TSP-1/ mice (*, P < 
0.05; n = 10 per group; age 8 wk). (D) Morphometric analysis of vascular-
ized areas with lymphatic vessels in sutured corneas of WT mice treated 
with three subconjunctival injections and topical eye drops (x3 daily) of 
recombinant human (rh) TSP-1 in comparison to control (*, P < 0.05;  
n = 8 per group, age 8 wk). Error bars indicate SD.1086 Thrombospondin-1 inhibits lymphangiogenesis | Cursiefen et al.
TSP-1 (Lawler, 2000, 2002; Armstrong and Bornstein, 2003), 
we next evaluated whether corneas from CD36/ mice re-
sembled those from TSP-1/ mice with respect to the in-
creased lymphvascular area under inflammatory conditions. 
We examined suture-induced, inflammation-associated cor-
neal lymphangiogenesis in CD36/ mice. As seen in Fig. 4, 
we found a significantly greater degree of lymphangiogenesis 
in CD36/ mice compared with age-matched WT controls. 
These results do resemble those seen in TSP-1/ mice. 
Therefore, these data are also supportive of an indirect inhibi-
tory effect exerted by TSP-1 on lymphangiogenesis involving 
CD36-mediated signaling events in macrophages.
The TSP-1 receptor CD36 is expressed on corneal 
macrophages, but not significantly on lymphatic vessels
Blood vascular endothelial cells are known to strongly express 
CD36 and ligation of this receptor by TSP-1 has been previ-
ously reported to induce apoptosis in these cells (Jiménez   
et al., 2000; Lawler, 2000, 2002; Armstrong and Bornstein, 
2003). Thus, the antihemangiogenic effect of TSP-1 is medi-
ated via CD36 on vascular endothelium. Based on this concept, 
we analyzed whether TSP-1 might exert its antilymphangio-
genic effect via CD36 on lymphatic endothelial cells. To do 
this, we examined the expression of CD36 in the cornea and 
especially on resting limbal lymphatic vessels. As depicted in 
Fig. 5 A, there was a strong expression of CD36 on resident 
CD11b+ corneal macrophages. However, there was no obvi-
ous colocalization of CD36 with LYVE-1+++ lymphatic ves-
sels (Fig. 5 B). This finding is consistent with previous studies 
that were unable to demonstrate a significant expression of 
factor VEGF-C in the adult mouse cornea and corresponds 
with the increased numbers of macrophages. This observation 
is consistent with the noted increase in corneal lymphvascular 
areas in older TSP-1/ mice. Furthermore, macrophages 
infiltrating the peritoneal cavity in response to an inflammatory 
stimulus such as thioglycollate, harvested from young TSP-1/ 
mice,  expressed  significantly  increased  levels  of VEGF-C 
compared with those derived from age-matched WT mice 
(Fig. 3 D). These results further support the increased lymph-
angiogenesis detectable in younger TSP-1/ mice in re-
sponse to suture-induced inflammation. Together, these results 
strongly suggest that TSP-1 exerts its antilymphangiogenic effect 
by reducing tissue levels of lymphangiogenic VEGF-C pre-
sumably by regulating its secretion from macrophages.
Increased inflammation-induced lymphangiogenesis  
in CD36/ mice
The  coincident  increase  in  macrophages  and VEGF-C  in 
TSP-1/ corneas points to the possibility that these corneal 
macrophages are involved in bringing about the antilymphan-
giogenic effect of TSP-1. In other words, TSP-1 may influ-
ence the ability of resident macrophages to secrete VEGF-C 
and regulate lymphangiogenesis. To determine if expression 
of VEGF-C by corneal macrophages may be regulated via 
their receptor CD36, which is a well-known receptor for 
Figure 3.  Increased transcription of the lymphangiogenic growth 
factor VEGF-C in TSP-1/ mice. VEGF-C mRNA levels in corneas of  
8-wk-old (A) and 6-mo-old (B) TSP-1/ mice in comparison to WT con-
trols. (C) Flow cytometric detection of CD11b+ macrophages in the cor-
neas harvested from 6-mo-old TSP-1/ mice (24.6%) compared with WT 
controls (19.7%). (D) Expression of VEGF-C in thioglycollate-elicited macro-
phages from TSP-1/ mice (age 8 wk) compared with WT mice detected 
by real-time PCR. Corneas were pooled from five mice per group in each 
experiment. Expression of VEGF-C relative to the GAPDH in four PCR reac-
tions per RNA sample is indicated. *, P < 0.05 compared with WT control. 
Error bars indicate SD.
Figure 4.  Increased inflammation-induced lymphangiogenesis in 
CD36/ mice. Representative segments of corneal flat mounts from WT 
(A) and a CD36/ (B) mice. (C) Morphometric comparison of lymphvas-
cularized area between WT control and CD36/ mice (*, P < 0.05; n = 10 
per group; age 8 wk). Li, limbal vascular arcade bottom; center of the 
cornea, top; flat mount stained with LYVE-1, red (lymphatic vessels);  
L, lymph vessels. Error bars indicate SD.JEM VOL. 208, May 9, 2011 
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we first irradiated CD36/ mice and reconstituted them 
with normal WT bone marrow cells. As a control, irradiated 
WT mice were also reconstituted with WT bone marrow 
cells. We then compared the degree of hemangiogenesis and 
lymphangiogenesis in these animals in response to suture-
induced inflammation. At 8 wk after bone marrow reconsti-
tution,  no  significant  difference  was  detectable  between 
CD36/ mice reconstituted with WT bone marrow and 
the control mice in the degree of hemangiogenesis (P > 
0.05; NS) and lymphangiogenesis (P > 0.05; NS; Fig. 5 C). 
These results clearly indicate that reconstitution with WT 
bone marrow that presumably restored cornea with CD36-
expressing  macrophages  reversed  the  prolymphangiogenic 
corneal environment in CD36/ mice. Our results there-
fore confirm an indirect inhibitory effect of TSP-1 on cor-
neal inflammation–associated lymphangiogenesis via CD36 
expressed on local macrophages.
Expression of VEGF-C in macrophages is regulated  
by TSP-1 via CD36
It is well established that binding of TSP-1 to CD36 on 
macrophages  is  a  prerequisite  to  the  activation  of  latent 
TGF (Yehualaeshet et al., 1999, 2000; Chen et al., 2009a,b; 
Wang et al., 2010). To determine if this TSP-1–CD36 inter-
action can inhibit VEGF-C expression in macrophages, we 
first compared  VEGF-C expression in thioglycollate-elicited 
macrophages derived from WT and CD36/ mice. A sig-
nificantly  reduced  expression  of VEGF-C  in  the  latter   
(Fig. 6 A; P < 0.05) correlates with their previously re-
ported reduced ability to generate biologically active TGF 
(Yehualaeshet  et  al.,  1999)  and  to  induce VEGF-C  via 
TGFRI ligation in peritoneal macrophages (Oka et al., 
2008).  Consistent  with  these  studies,  exogenously  pro-
vided TGF successfully increases expression of VEGF-C 
in CD36/ macrophages as detected by increased message 
as well as the protein level compared with WT control cells 
(Fig. 6, B and C; P < 0.05). We next treated WT or CD36/ 
macrophages with TSP-1 and as shown in Fig. 6 D. Al-
though inhibition of VEGF-C was detectable in WT mac-
rophages,  no  such  inhibition  was  detected  in  CD36/ 
macrophages (P < 0.05).
To further confirm that the inhibitory effect of TSP-1 on 
VEGF-C expression is indeed delivered via CD36, we used a 
TSP-1–derived  antagonistic  peptide  that  binds  CD36  and 
can block further binding of TSP-1 to this receptor. As shown 
in Fig. 6 E the inhibitory effect of TSP on the expression of 
VEGF-C by WT macrophages was not affected by the con-
trol peptide. In contrast, the CD36-blocking peptide partially, 
albeit significantly, reversed this inhibition.
Similar to  VEGF-C, the expression of  VEGF-D was inhib-
ited by TSP-1 in WT macrophages (Fig. 6 F), whereas VEGF-A   
expression remained unaltered (Fig. 6 G).
These  results  clearly  demonstrate  that  the  ligation  of 
TSP-1 to CD36 on macrophages prevents their expression of 
lymphangiogenic factors, and thus explains the indirect in-
hibitory effect of TSP-1 on corneal lymphangiogenesis.
CD36 in skin lymphatic vessels (Hawighorst et al., 2002). The 
absence of CD36 on corneal lymphatic vessels further sup-
ports an indirect antilymphangiogenic effect of TSP-1 via its 
ligation on resident macrophages.
Reconstitution of CD36/ mice with CD36+/+ bone  
marrow reverses the prolymphangiogenic phenotype  
of CD36/ mice
Our results so far point to the CD36 receptor as a potential 
mediator of antilymphangiogenic effect of TSP-1. Expres-
sion of this receptor on resident corneal macrophages sug-
gests these cells as likely candidates involved in bringing 
about the indirect effect of TSP-1 on lymphangiogenesis. 
Macrophages are bone marrow–derived cells and are potent 
amplifiers of lymphangiogenic signals during inflammation 
(Cursiefen et al., 2004b; Kerjaschki, 2005; Maruyama et al., 
2007). To evaluate their role in corneal lymphangiogenesis, 
Figure 5.  CD36 on macrophages regulates the lymphangiogenic 
response in the cornea. (A) The macrophage marker CD11b (green) and 
the TSP-1 receptor CD36 (red) are colocalized (yellow) on monocytic cells 
in the normal corneal stroma. (B) The specific lymphatic marker LYVE-1 
(red) is not colocalized with antibodies against CD36 (green), and is ex-
pressed by blood vessels detectable at the limbus. (C) Morphometric com-
parison of corneal lymphvascularized area between WT (n = 8) control 
and CD36/ (n = 9) mice (reconstituted with WT bone marrow) in a 
mouse model of inflammatory corneal neovascularization. Error bars indi-
cate SD.1088 Thrombospondin-1 inhibits lymphangiogenesis | Cursiefen et al.
In contrast, 
it  remains 
unclear how 
the ingrowth of lymphatic vessels (into alymphatic tissues) is 
prevented. The cornea is normally devoid of both blood and 
lymphatic vessels, but can be invaded by both vessel types   
after severe inflammatory insults (Cursiefen et al., 2002; Kubo 
et al., 2002). Using the normally alymphatic cornea as a 
model, we identify TSP-1 as a novel endogenous inhibitor of 
lymphangiogenesis. The normal cornea contains both mes-
sage and protein for TSP-1 (Cursiefen et al., 2004c), especially 
in the inner and outer layers (basal epithelium and Descemet’s 
membrane; Hiscott et al., 1997). Two of our findings suggest 
that TSP-1 is likely to be one of several antilymphangiogenic 
factors within the cornea: (1) there was only mild spontane-
ous lymphangiogenesis in TSP-1/ mice and (2) the effect 
was only observed in older mice. Therefore, other mechanisms 
such as the recently identified role of a splice variant of sVEGFR2 
in maintaining corneal alymphatic status (Albuquerque et al., 
2009) might be at work in TSP-1/ mice. Furthermore, 
based on increased lymphatic vessels detectable in the TSP-1/ 
cutaneous tissue, we conclude that the inhibitory effect of 
TSP-1 on lymphangiogenesis is also applicable in nonim-
mune privileged sites.
Although  mildly  increased  corneal  lymphvascular  area 
was detectable in older CD36/ mice (unpublished data), in 
younger mice a profound increase in corneal lymphangio-
genesis was noted in an inflammatory milieu similar to that 
seen in TSP-1/ mice. These results implicated CD36 as a 
DISCUSSION
In this study, we demonstrate for the first time that TSP-1 
plays a crucial role in the regulation of inflammatory lymphan-
giogenesis. We show that this multifunctional matrix protein 
regulates the expression of VEGF-C at the mRNA level in 
macrophages. In addition, we were able to demonstrate that 
this regulation is mediated via the receptor CD36. Using a 
model of inflammatory lymphangiogenesis in an otherwise 
angiogenically privileged site, such as the cornea, we demon-
strate that the absence of TSP-1 leads to a significant increase 
in lymphangiogenesis. This observation underscores the im-
portance of TSP-1 in maintaining the avascular status of the 
immune-privileged corneal tissue. Our findings are further 
supported by the observation that 6-mo-old TSP/ mice 
develop  spontaneous  corneal  lymphangiogenesis  and,  in 
parallel, exhibit a massive increase in the lymphangiogenic 
growth factor VEGF-C in comparison to young animals.
Whereas the pro- and antihemangiogenic factors balanc-
ing the process of blood vessel outgrowth (hemangiogenesis) 
have received much attention over the past years with a large 
array of known factors (Folkman, 1995; Carmeliet and Jain, 
2000; Chang et al., 2001), less is known about the factors in-
volved in the induction and prevention of lymphatic vessels 
(lymphangiogenesis). Both the VEGF family (VEGF-A, -C, and 
-D; Folkman, 1995; Carmeliet and Jain, 2000; Enholm et al., 
2001;  Veikkola et al., 2001; Nagy et al., 2002; Podgrabinska et al., 
2002; Saaristo et al., 2002; Stacker et al., 2002; Rissanen   
et al., 2003; Cursiefen et al., 2004b) and bFGF can induce   
the outgrowth of lymphatic vessels (Kubo et al., 2002).   
Figure 6.  TSP-1 down-regulates expression of 
VEGF-C in macrophages via CD36. Relative expres-
sion of VEGF-C (A, B, D, and E), VEGF-D (F), and VEGF-A 
(G) message and VEGF-C protein (C) in thioglycollate-
elicited macrophages from WT or CD36/ mice:  
(A) freshly harvested, (B–G) cultured in the absence or 
presence of TGF2, TSP-1, or CD36 blocking and control 
peptides. Total RNA harvested from macrophages was 
subjected to real-time PCR analysis to detect expression 
of VEGF-C, VEGF-D, and VEGF-A mRNA and to detect 
VEGF-C protein culture supernatants were analyzed by 
ELISA. Although freshly harvested CD36/ macro-
phages express significantly lower levels of VEGF-C 
compared with WT controls (A) these macrophages 
retain their ability to respond to exogenously provided 
TGF2 in culture by increasing expression of VEGF-C 
(both message [B] and protein [C]) compared with WT 
controls. Inhibition of VEGF-C expression detectable in 
WT macrophages cultured with TSP-1 (5 µg/ml) is not 
detected in similarly treated CD36 / macrophages (D). 
In the presence of CD36-binding TSP-1–derived peptide 
capable of blocking CD36–TSP-1 interaction (CD36 
blocking peptide), the inhibitory effect of TSP-1 on the 
VEGF-C expression in WT macrophages is significantly 
reversed (E). Treatment of WT macrophages to TSP-1 
also inhibited the expression of the lymphangiogenesis 
factor VEGF-D (F), but not that of predominantly 
hemangiogenic factor VEGF-A (G). Expression of VEGF-C, 
VEGF-D, and VEGF-A relative to the GAPDH in four 
independent PCR reactions per RNA sample is indicated. 
*, P < 0.05 compared with WT, untreated or indicated 
control. Error bars indicate SD.JEM VOL. 208, May 9, 2011 
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via TSP-1–CD36 interactions dominate, preventing VEGF-C 
synthesis. In the absence of CD36, TSP-1 fails to initiate 
the inhibitory signal allowing TGF–TGFR1 interaction 
to induce expression of VEGF-C, which in turn results in 
similar spontaneous outgrowth of corneal lymphatic ves-
sels in the CD36/ mouse (unpublished data) as shown in 
TSP/ mice.
The cornea is one of the few avascular tissues present in 
the adult body, and the only one that can secondarily become 
vascularized by both blood and lymphatic vessels (Cursiefen 
et al., 2002). Whereas the corneal angiogenic privilege is re-
dundantly organized so that absence of one or more anti-
hemangiogenic factors does not cause spontaneous ingrowths 
of blood vessels (Cursiefen et al., 2004c), our present data sug-
gest that the antilymphangiogenic privilege of the cornea is 
not redundantly organized. This may be related to the fact 
that lymphatic vessels (in contrast to blood vessels) do not 
compromise corneal transparency, an evolutionarily highly 
conserved quality (Streilein, 2003).
The identification of TSP-1 as an endogenous inhibitor of 
lymphangiogenesis and a factor that down-regulates  VEGF-C 
expression opens new avenues to understand the complex 
interaction of angiogenesis, lymphangiogenesis, and immune 
response in, for example, (corneal) transplantation (Mwaikambo 
et al., 2006), tumorigenesis, and metastasis (Zhang and Lawler, 
2007; Martin-Manso et al., 2008). In this study, we also dem-
onstrate successful inhibition of inflammation-induced cor-
neal lymphangiogenesis by local application of TSP-1. Thus, 
our work clearly presents the therapeutic implications of 
novel antilymphangiogenic effect of TSP-1.
MATERIALS AND METHODS
Mice. TSP-1/ mice (C57BL/6 background) were originally received from 
the laboratory of J. Lawler (Beth Israel-Deaconess Medical Center, Harvard 
Medical School, Boston, MA). CD36/ mice (C57BL/6 background) were 
obtained from the laboratory of M. Freeman (Massachusetts General Hospi-
tal, Harvard Medical School, Boston, MA). These mice were subsequently 
bred at the animal facility at Schepens Eye Research Institute (Boston, MA). 
WT control C57BL/6 mice were purchased from The Jackson Laboratory. 
Mice were examined using slit-lamp technology for signs of angiogenesis 
before euthanasia. All animals were treated in accordance with the ARVO 
Statement for the Use of Animals in Ophthalmical and  Vision Research. Each 
mouse was anesthetized by intraperitoneal injection of a mixture of 4 mg 
ketamine and 0.1 mg xylazine before all surgical procedures.
Induction and quantification of corneal hemangiogenesis and lymph­
angiogenesis. To induce corneal neovascularization, the established model 
of suture-induced inflammatory corneal neovascularization was applied as 
previously described (Cursiefen et al., 2004a,b). We have shown that suture 
placement into the corneal stroma in this model induces early and parallel 
outgrowth of both blood and lymphatic vessels into the normally avascular 
cornea (Cursiefen et al., 2004a,b). In brief, mice were put under general 
anesthesia, and 3 intrastromal 11–0 nylon sutures were placed in the corneal 
stroma with 2 incursions extending over 120° of corneal circumference each. 
This creates an inflamed hemvascularized and lymphvascularized cornea. 
Sutures were left in place for 7 d.
For local treatment with recombinant human TSP-1 (R&D Systems), 
mice received a subconjunctival injection of 50 µl TSP-1 in PBS (50 ng/50 µl) 
24 h before suture placement. Just before suture placement, the corneal epi-
thelium was scraped off to maintain good penetration of subsequently   
potential TSP-1 receptor likely to regulate lymphangiogene-
sis. Because of the absence of CD36 on lymphatic vessels 
(Hawighorst et al., 2002), unlike on blood vessels, we demon-
strate that the antilymphangiogenic effect of TSP-1 in the 
cornea is mediated indirectly via CD36-expressing local macro-
phages. Under inflammatory conditions, corneal macrophages 
are known to contribute to lymphangiogenesis, presumably 
by serving as a source of  VEGF-C (Maruyama et al., 2005). In 
TSP-1/ corneas, increased expression of VEGF-C was ac-
companied with an increased numbers of macrophages. These 
results are consistent with an increased expression of a macro-
phage chemotactic factor, MCP-1, reported to be one of the 
inflammatory mediators expressed in corneas derived from 
older TSP-1/ mice (Turpie et al., 2009). These mice were 
reported to spontaneously develop ocular surface inflamma-
tion with increasing age. Finally, the reversal of inflammation 
induced corneal lymphangiogenesis in CD36/ mice by re-
constitution with WT bone marrow confirms the relevance 
of CD36 expressed on corneal macrophages in TSP-1–mediated 
prevention  of  lymphangiogenesis.  Consistent  with  these   
in vivo results, we noted in our in vitro experiments that exoge-
nously added TSP-1 failed to inhibit VEGF-C expression in 
peritoneal macrophages with blocked or missing CD36 recep-
tor. These results highlight an important role of monocytic 
cells in regulating inflammatory lymphangiogenesis in addi-
tion to hemangiogenesis (Schoppmann et al., 2002; Cursiefen 
et al., 2004b; Kerjaschki, 2005; Maruyama et al., 2005).
Contrary to our expectations, unlike TSP-1/ macro-
phages, CD36/ macrophages constitutively expressed sig-
nificantly reduced levels of VEGF-C. This is likely caused by 
their reduced levels of endogenous activated TGF, as exog-
enously  provided TGF  enhanced VEGF-C  expression  in 
CD36/ macrophages. This result matches with a recent study 
involving a chronic mouse peritonitis model (Oka et al., 2008) 
where the authors report absence of induction of VEGF-C, 
whereas  their  results,  in  fact,  demonstrate  significantly  re-
duced levels of  VEGF-C in the absence of endogenous TGF-
driven signals. Therefore, a decline in constitutive VEGF-C 
expression in CD36/ macrophages is possible because their 
endogenous TGF signaling is disrupted (Wang et al., 2009). 
Together, these observations imply that the inhibitory role at-
tributed to TGF in lymphangiogenesis may in fact be medi-
ated indirectly by TSP-1 bound to CD36 during activation of 
endogenously produced latent TGF. However potential sig-
naling via TSP-1–CD36 interaction in macrophages remains 
largely unknown. Similar to VEGF-C, we noted inhibitory 
effects  of TSP-1  on VEGF-D  expressed  by  macrophages, 
whereas their VEGF-A expression remained unaltered.
Based on our observations, some of the complex receptor 
ligand interactions that lead to induction or prevention of 
lymphangiogenesis can be depicted as shown in Fig. S1. In 
WT macrophages, inhibitory signals mediated by endogenous 
TSP-1 negate an increased expression of  VEGF-C induced by 
endogenous activated TGF resulting in no net change in 
VEGF-C expression. However when these WT macrophages 
encounter TSP-1 in their environment, the inhibitory signals 1090 Thrombospondin-1 inhibits lymphangiogenesis | Cursiefen et al.
Real­time PCR. Total RNA was isolated from the corneas or macrophages 
from WT or TSP-1/ mice (8 or 24 wk; n = 4–5) using RNA STAT-60   
kit (Tel-Test, Inc.) according to the manufacturer’s instructions. cDNA was   
synthesized by reverse transcribing RNA using oligo-dT and M-MLV RT   
(Promega). SYBR Green real-time PCR assay (Invitrogen) was used to de-
termine relative quantitative expression of selected genes. Sequences of the   
primers used for these genes are as follows: VEGF-C, forward 5-GTTA-
CAGAAGACCGTGTGCGAATC-3  and  reverse  5-GATGGGACACA-
GCGGCATA-3;  VEGF-A,  forward  5-CTGCCGTCCGATTGAGA-3 
and  reverse  5-ACTCCAGGGCTTCATCGTTAC-3; VEGF-D,  forward 
5-ACATCAGTGCCCGAGTTAG-3 and reverse 5-AAGCACTTACA-
ACCCGTATGG-3; GAPDH, forward 5-CGAGAATGGGAAGCTT-
GTCA-3  and  reverse  5-AGACACCAGTAGACTCCACGACAT-3. 
Amplification reactions were set up using SurePRIME-&GO master mix 
(MP Biomedicals) in triplicate with the following thermal profile: 50°C for 
2 min; 1 cycle 95°C for 15 min; 1 cycle 95°C for 15 s; 52–55°C for 1 min; 
72°C for 30 s; 40 cycles, 95°C for 15 s; 1 cycle on ABI Prism analyzer (Applied 
Biosystems). Fluorescence signal generated at each cycle was analyzed using 
system software. The threshold cycle (Ct) values were used to determine rela-
tive quantitation of gene expression with GAPDH as a reference gene.
VEGF­C ELISA. Culture supernatants derived from macrophages in some 
experiments were analyzed for the levels of  VEGF-C protein using an ELISA 
kit (eBioscience). The antibodies used in this assay were reported to detect 
mouse protein (Weich et al., 2004). The assay was performed according to the 
manufacturer’s instructions.
Flow cytometric analysis of cornea. Single-cell suspensions were pre-
pared from corneal samples using collagenase digestion, as previously described 
(Saban et al., 2009). In brief, corneas were removed and minced into small 
fragments, followed by digestion with 2 mg/ml collagenase type IV (Sigma-
Aldrich) and 0.05 mg/ml DNase I (Roche) for 1 h at 37°C with agitation. 
The suspension was then triturated through a 10-ml syringe to homogenize 
the remaining tissue, and filtered through a 70-µm cell strainer. Once in single-
cell suspension, all samples underwent Fc receptor blockade via incubation 
with anti-CD16/CD32 (BD) at 4°C in 0.5% BSA (Sigma-Aldrich). Sub-
sequent antibody labeling included anti-CD11b and CD45 (BD). Staining 
with all antibodies was analyzed with the appropriate isotype controls.
Bone marrow transplantation. Bone marrow transplantation was per-
formed as described previously (Cursiefen et al., 2004b; Maruyama et al., 
2005). In brief, age-matched CD36/ mice and WT controls (C57BL/6) 
were whole body irradiated, and then kept under sterile housing conditions. 
Within 3 d after irradiation, bone marrow transplantation was performed by 
injecting 107 cells from nonirradiated WT bone marrow into the tail vein for 
both irradiated CD36/ and irradiated WT mice (n = 5). After 8 wk, cor-
neal neovascularization was induced in both groups by placement of 11–0 
nylon sutures intrastromally. Mice were sacrificed after 1 wk, and the degree 
of corneal hemangiogenesis and lymphangiogenesis quantified in CD31/
LYVE-1 stained corneal flat mounts as described in Induction and quantifi-
cation of corneal hemangiogenesis and lymphangiogenesis.
Statistical analysis. Statistical significance was analyzed by Mann-Whitney 
test. Differences were considered significant at P < 0.05. Each experiment 
was performed at least three times. Graphs were drawn using GraphPad 
Prism, version 3.02.
Online supplemental material. Fig. S1 shows the mechanism VEGF-C 
expression is regulated by CD36–TSP interaction in macrophages. Online 
supplemental material is available at http://www.jem.org/cgi/content/full/ 
jem.20092277/DC1.
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Streilein for help with the mouse irradiation and bone marrow transplantation 
applied TSP-1 eye drops. After suture placement, mice were treated with 
TSP-1 eye drops (50 ng/100 µl) three times daily until the end of the experi-
ment and additionally received 50 ng TSP-1 via a subconjunctival injection 
(50 µl) on day 1 and 3 after the operation while under general anesthesia.
After 7 d, mice were euthanized and the cornea, including the limbus, 
was excised and flat-mount double-immunohistochemistry was performed 
as previously described (Cursiefen et al., 2004a,b). Corneal flat mounts were 
rinsed in PBS, fixed in acetone, rinsed in PBS, blocked in 2% bovine serum 
albumin, stained with FITC-conjugated CD31 overnight (rat -mouse; 
1:100; Santa Cruz Biotechnology, Inc.), washed, blocked, stained with LYVE-1 
(rabbit -mouse; 1:100; a lymphatic endothelium-specific hyaluronic acid 
receptor; gift from D.G. Jackson, Oxford University, Oxford, England, UK; 
Cursiefen et al., 2002, 2004a,b) washed, blocked, and stained with a Cy3-
conjugated  secondary  antibody  (goat  -rabbit;  1:100;  Jackson  Immuno-
Research Laboratories). The whole mounts were analyzed using an Axiophot 
microscope (Carl Zeiss). Digital pictures of the flat mounts were taken using 
Spot Image Analysis system. The area covered by LYVE-1+++/CD31+ lym-
phatic vessels (Fig. 1 C) was measured morphometrically on these flat mounts 
using the ImageJ software (National Institutes of Health). The total corneal 
area was outlined using the innermost vessel of the limbal arcade as the bor-
der. The total area of lymphangiogenesis was then normalized to the total 
corneal area, and the percentage of the cornea covered by lymphatic vessels 
was calculated.
Quantification of ear skin lymphangiogenesis. The analysis of ear skin 
for hemangiogenesis and lymphangiogenesis is described elsewhere (Cho   
et al., 2006; Machnik et al., 2009). We used this assay to compare the lym-
phatic vessel status in an angiogenic unprivileged site of TSP-1/ mice 
against WT C57BL/6 mice.
Naive 10-d-old (p10) and 30-d-old (p30) TSP-1/ and WT mice were 
sacrificed and their ears were harvested. Whole mounts of the ears were fixed 
in 5% paraformaldehyde for 24 h, washed in PBS, blocked with 3% goat   
serum in 0.3% Triton-X 100 in PBS, stained with rabbit anti–mouse LYVE-1 
(1:200; AngioBio), washed, blocked, stained with a goat anti–rabbit Cy-3 
(1:100; Dianova), washed, and analyzed using a BX51 fluorescence micro-
scope (Olympus). Quantitative analysis were done with the Cell^F image 
analysis program (Olympus). The total area of lymphatic vessels was normal-
ized to the total ear area, and the percentage of the ear section covered by 
lymphatic vessels was calculated.
Transmission electron microscopy. To clearly identify intrastromal iso-
lated lymphatic vessels in TSP-1/ corneas, transmission electron micros-
copy was performed on freshly harvested corneas of aged TSP-1/ on 
C57BL/6 background as previously described (Cursiefen et al., 2002).
Immunohistochemistry for CD11b, CD36, CD31, and LYVE­1. Indi-
rect immunohistochemistry was performed as previously described (Cursiefen 
et al., 2002, 2004a,b) on corneal whole mounts and frozen sections of normal 
corneas using antibodies against CD11b (rat monoclonal; BD), LYVE-1 (rabbit 
polyclonal; gift from D.G. Jackson), CD31 (rat monoclonal; Santa Cruz Biotech-
nology, Inc.), and CD36 (mouse monoclonal; Santa Cruz Biotechnology, Inc.).
Macrophage culture. Peritoneal exudate cells were collected from the 
peritoneal lavage of mice (age 6 wk) injected with 2% thioglycollate 3 d 
before. Cells were cultured in serum-free RPMI-1640 for an hour at 37°C, 
and nonadherent cells were discarded. Adherent cells are predominantly 
(>95%) F4/80+ macrophages as previously determined by flow cytometry. 
Macrophages were cultured in serum-free RPMI-1640 in the presence or 
absence of 5 µg/ml TSP (Hematologic Technologies, Inc.) for 24 h. In 
some experiments 5 ng/ml TGF2 (R&D Systems) or 50 µM CD36-
binding peptide (CSVTCG) or control peptide (ANKHYF) were added to 
the culture. Peptides were synthesized by Bio-Basic Inc. Total RNA was 
harvested from cultured cells pooled from 3–4 wells per group and sub-
jected to real-time PCR analysis. Three to four PCR reactions were per-
formed per RNA sample.JEM VOL. 208, May 9, 2011 
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